Availability of Pharmacogenetic and Pharmacogenomic Information in Anticancer Drug Monographs in France: Personalized Cancer Therapy

Abstract

We believe that the lack of pharmacogenomic and pharmacogenetic information in drug monographs reflects the relative newness of the discipline. However, pharmacogenetics and pharmacogenomics can offer valuable information for improving the safety of drugs, reducing toxicity and predicting nonresponders. The drugs might then be incorporated into clinical practice through several strategies, including increased drug labeling and better education of healthcare professionals.

Pharmacogenomics

“…Pharmacogenomics is defined as the study of influence of genetic variations on individual differences in response to pharmacological agents. [1] Pharmacogenetics is a subset of pharmacogenomics and is the study of the influence of variation in DNA sequence on differential drug responses. [1] Apart from variation in the DNA sequence, pharmacogenomics also includes epigenetics or transcriptomic changes.…”

“…[1] Pharmacogenetics is a subset of pharmacogenomics and is the study of the influence of variation in DNA sequence on differential drug responses. [1] Apart from variation in the DNA sequence, pharmacogenomics also includes epigenetics or transcriptomic changes. Variations in genetic makeup at any of the below-mentioned steps within a population may lead to unpredictable clinical responses and toxicity profiles.…”